Topoisomerase I Inhibitors: Current Use and Prospects

[1]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Greil,et al.  Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT). , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Dan L. Longo Bruce A. Chabner.  Cancer chemotherapy and biotherapy , 2013 .

[4]  B. Cho,et al.  Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. , 2010, Lung cancer.

[5]  J. W. Kim,et al.  A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer. , 2010, Lung cancer.

[6]  S. Blank,et al.  Oxaliplatin plus continuous infusion topotecan: First stage of an ongoing phase II study for recurrent ovarian cancer: A New York Cancer Consortium study (#N01-CM62204). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Teruhiko Yoshida,et al.  Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients , 2010, Cancer Chemotherapy and Pharmacology.

[8]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[9]  C. Bokemeyer,et al.  A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  D. Cella,et al.  Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  O. Ganslandt,et al.  Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme. , 2009, International journal of radiation oncology, biology, physics.

[13]  T. Furuta.  Pharmacogenomics in chemotherapy for GI tract cancer , 2009, Journal of Gastroenterology.

[14]  S. Yokoyama,et al.  [Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[15]  R. Greil,et al.  Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Kubicka,et al.  Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Crowley,et al.  Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Beom Soo Shin,et al.  Use of an Anti-Vascular Endothelial Growth Factor Antibody in a Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy , 2009, Journal of Pharmacology and Experimental Therapeutics.

[19]  Y. Pommier,et al.  The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives , 2009, Molecular Cancer Therapeutics.

[20]  T. Conroy,et al.  A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  D. Alberts,et al.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  John A Butman,et al.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Jeffrey W. Clark,et al.  Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[24]  A. Friedman,et al.  Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas , 2008, Clinical Cancer Research.

[25]  F. Bonnetain,et al.  Phase III trial of chemotherapy with or without irinotecan in the front-line treatment of metastatic colorectal cancer in elderly patients (FFCD 2001–02 trial). Results of a planned interim analysis , 2008 .

[26]  J. Zaluski,et al.  Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  K. Inui,et al.  [Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction]. , 2008, Gan to kagaku ryoho. Cancer & chemotherapy.

[28]  M. Ychou,et al.  Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases , 2008, Cancer Chemotherapy and Pharmacology.

[29]  R. Greil,et al.  Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer: First results of a multicenter phase II trial (AGMT Gastric- 2 , 2008 .

[30]  M. Chamberlain,et al.  CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma , 2008, Journal of Neuro-Oncology.

[31]  M. Chamberlain,et al.  Salvage chemotherapy with CPT‐11 for recurrent temozolomide‐refractory anaplastic astrocytoma , 2008, Cancer.

[32]  R. Stephens,et al.  Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Panetta,et al.  Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients , 2007, Clinical Cancer Research.

[35]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Fuchs,et al.  Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  E. Shimizu,et al.  Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. , 2007, Therapeutic drug monitoring.

[38]  F. Giuliante,et al.  Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases , 2007, British Journal of Cancer.

[39]  D. Shin,et al.  Irinotecan plus carboplatin for patients with extensive-disease small cell lung cancer: P1-226 , 2007 .

[40]  P. Foggi,et al.  Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma , 2007, British Journal of Cancer.

[41]  H. Naman,et al.  Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer , 2007, British Journal of Cancer.

[42]  Richard J Stephens,et al.  Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial , 2007, The Lancet.

[43]  J. von Pawel,et al.  Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  L. Crinò,et al.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Darell D. Bigner,et al.  Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[46]  D. Alberts,et al.  Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer. , 2006, Gynecologic oncology.

[47]  T. Ciuleanu,et al.  Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Ho,et al.  A novel MDR1 G1199T variant alters drug resistance and efflux transport activity of P-glycoprotein in recombinant Hek cells. , 2006, Journal of pharmaceutical sciences.

[49]  L. Schwartz,et al.  Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  H. Lenz,et al.  Molecular determinants of irinotecan efficacy , 2006, International journal of cancer.

[51]  Balram Chowbay,et al.  Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients , 2006, Pharmacogenetics and genomics.

[52]  L. Mariani,et al.  Irinotecan, Fluorouracil and Folinic ACID (FOLFIRI) as Effective Treatment Combination for Patients with Advanced Gastric Cancer in Poor Clinical Condition , 2006, Tumori.

[53]  A. Reuss,et al.  Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. , 2006, Journal of the National Cancer Institute.

[54]  H. Saka,et al.  Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors , 2006, Cancer Chemotherapy and Pharmacology.

[55]  H. Hurwitz,et al.  A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors , 2006, Cancer Chemotherapy and Pharmacology.

[56]  F. Shepherd,et al.  Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  N. Hanna,et al.  Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  H. Hochster,et al.  Topotecan continuous infusion: CA-125 responses including patients pretreated with other schedules of topotecan. , 2006, The oncologist.

[59]  J. Bae,et al.  Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma , 2006, British Journal of Cancer.

[60]  E. Plimack,et al.  Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study. , 2006, Gynecologic oncology.

[61]  Jeffrey W. Clark,et al.  A Phase II Trial of Irinotecan in Patients with Previously Untreated Advanced Esophageal and Gastric Adenocarcinoma , 2005, Digestive Diseases and Sciences.

[62]  Sang Lee,et al.  Phase I Study of Combined Pegylated Liposomal Doxorubicin with Protracted Daily Topotecan for Ovarian Cancer , 2005, Clinical Cancer Research.

[63]  C. Bokemeyer,et al.  Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  D. Miller,et al.  Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  J. Herndon,et al.  Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). , 2005, Lung cancer.

[66]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[67]  Shigeki Sugiura,et al.  ROLE OF ORGANIC ANION TRANSPORTER OATP1B1 (OATP-C) IN HEPATIC UPTAKE OF IRINOTECAN AND ITS ACTIVE METABOLITE, 7-ETHYL-10-HYDROXYCAMPTOTHECIN: IN VITRO EVIDENCE AND EFFECT OF SINGLE NUCLEOTIDE POLYMORPHISMS , 2005, Drug Metabolism and Disposition.

[68]  J. Zaluski,et al.  Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  D. Sargent,et al.  Mortality associated with daily bolus 5‐fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin , 2004, Cancer.

[70]  F. Zunino,et al.  Efficacy of the Novel Camptothecin Gimatecan against Orthotopic and Metastatic Human Tumor Xenograft Models , 2004, Clinical Cancer Research.

[71]  D. Arsène,et al.  Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  P. Houghton,et al.  Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  B. Monk,et al.  Cisplatin and irinotecan in squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. , 2004, Gynecologic oncology.

[74]  A. Grothey,et al.  Capecitabine/ irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: Results of a randomized phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[76]  E. Thiel,et al.  Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan , 2004, Neurology.

[77]  E. Thiel,et al.  Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer , 2004, Cancer Chemotherapy and Pharmacology.

[78]  M. Gruber,et al.  Temozolomide in Combination With Irinotecan for Treatment of Recurrent Malignant Glioma , 2004, American journal of clinical oncology.

[79]  M. Ducreux,et al.  Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial , 2003, British Journal of Cancer.

[80]  A. Grothey,et al.  295 Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): updated results of a randomized phase II trial , 2003 .

[81]  Sharon Marsh,et al.  Irinotecan pathway genotype analysis to predict pharmacokinetics. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[82]  G. Broggi,et al.  Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma , 2003, Journal of Neuro-Oncology.

[83]  E. Raymond,et al.  Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[84]  W. Hinkelbein,et al.  A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma , 2003, International Journal of Colorectal Disease.

[85]  M. Tan,et al.  A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  M. Ducreux,et al.  Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[87]  J. Kuhn.  Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. , 2002, Oncology.

[88]  G. Hudes.  Boosting bioavailability of topotecan: what do we gain? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.

[90]  M. Bernstein,et al.  Influence of Phenytoin on the Disposition of Irinotecan: A Case Report , 2002, Journal of pediatric hematology/oncology.

[91]  J. Ajani,et al.  CPT‐11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma , 2002, Cancer.

[92]  K. Mori,et al.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. , 2002, The New England journal of medicine.

[93]  J. Berlin,et al.  A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[94]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[95]  D Guthrie,et al.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  J. Hoeijmakers.  Genome maintenance mechanisms for preventing cancer , 2001, Nature.

[97]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[98]  B. Giovanella,et al.  Combined Radiation and 9‐Nitrocamptothecin (Rubitecan) in the Treatment of Locally Advanced Pancreatic Cancer , 2000, Annals of the New York Academy of Sciences.

[99]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[100]  G. Weiss,et al.  A Phase II Trial of Topotecan in Esophageal Carcinoma: A Southwest Oncology Group Study (SWOG 9339) , 2000, Investigational New Drugs.

[101]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[102]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[103]  S. Lipsitz,et al.  Treatment of squamous cell esophageal cancer with topotecan: an Eastern Cooperative Oncology Group Study (E2293). , 2000, American journal of clinical oncology.

[104]  G. Schwartz,et al.  Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  H. Shibahara,et al.  A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma. , 1999, Japanese journal of clinical oncology.

[106]  C. Runowicz,et al.  Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  R. McLendon,et al.  Irinotecan therapy in adults with recurrent or progressive malignant glioma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  R. McLendon,et al.  Topotecan treatment of adults with primary malignant glioma , 1999, Cancer.

[109]  J. Carmichael,et al.  Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  J. Kuhn,et al.  Pharmacology of irinotecan. , 1998, Oncology.

[111]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[112]  K. Hasumi,et al.  A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. , 1998, Annals of the Academy of Medicine, Singapore.

[113]  J. O’Leary,et al.  Camptothecins: a review of their development and schedules of administration. , 1998, European journal of cancer.

[114]  H. Saka,et al.  UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[115]  H. Rosing,et al.  Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[116]  G. Schwartz,et al.  A phase II study of topotecan administered five times daily in patients with advanced gastric cancer. , 1997, American journal of clinical oncology.

[117]  D W Nebert,et al.  The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. , 1997, Pharmacogenetics.

[118]  A Gordon,et al.  Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  E. Estey,et al.  Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. , 1996, Blood.

[120]  K. Ushijima,et al.  [Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer]. , 1996, Nihon Sanka Fujinka Gakkai zasshi.

[121]  S. Sallan,et al.  Phase II evaluation of topotecan for pediatric central nervous system tumors , 1996 .

[122]  J. Verweij,et al.  Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. , 1996, British Journal of Cancer.

[123]  E. Eisenhauer,et al.  Phase II study of topotecan in patients with recurrent malignant glioma , 1996 .

[124]  J. Wanders,et al.  Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[125]  S. Baker,et al.  Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors , 1995, Cancer Chemotherapy and Pharmacology.

[126]  S. Baker,et al.  Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  T. Taguchi,et al.  [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[128]  H. Hochster,et al.  Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[129]  W. Furman,et al.  Phase I study of topotecan for pediatric patients with malignant solid tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[130]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[131]  F. D. Zeman.  Proceedings Of A Conference , 1949 .

[132]  B. Scheithauer,et al.  Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results , 2008, Journal of Neuro-Oncology.

[133]  R. Berardi,et al.  Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[134]  P. Wen,et al.  Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma , 2007, Journal of Neuro-Oncology.

[135]  M. Zucchetti,et al.  Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[136]  L. Seymour,et al.  A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer. , 2006, European journal of cancer.

[137]  Susan M. Chang,et al.  A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. , 2006, Neuro-oncology.

[138]  H. Lenz,et al.  Pharmacogenomics and colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[139]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  S. Balcerzak,et al.  Phase II trial of topotecan in advanced gastric cancer: A Southwest Oncology Group study , 2004, Investigational New Drugs.

[141]  L. Assersohn,et al.  Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[142]  E. Estey,et al.  Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study , 2004, Investigational New Drugs.

[143]  M. Chamberlain.  Salvage Chemotherapy with CPT-11 for Recurrent Glioblastoma Multiforme , 2004, Journal of Neuro-Oncology.

[144]  Y. Sugiyama,et al.  The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. , 2002, Drug metabolism and pharmacokinetics.

[145]  C. Verschraegen,et al.  The camptothecins : unfolding their anticancer potential , 2000 .

[146]  C. Takimoto,et al.  Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates , 1998, Cancer Chemotherapy and Pharmacology.

[147]  S. Culine,et al.  Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  P. Rougier,et al.  Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. , 1996, European journal of cancer.

[149]  P. Pantazis,et al.  The camptothecins : from discovery to the patient , 1996 .